Sam­sung Bioepis strikes deal for Ste­lara biosim­i­lar, but launch like­ly won't come in time for an IRA ex­emp­tion

Sam­sung Bioepis reached a deal this week that would al­low its Ste­lara biosim­i­lar hope­ful to launch in Feb­ru­ary 2025, adding to mount­ing com­pe­ti­tion against John­son & John­son’s an­ti-in­flam­ma­to­ry block­buster.

How­ev­er, it’s un­like­ly the can­di­date — or oth­ers un­der launch set­tle­ments with J&J — will amount to “mean­ing­ful com­pe­ti­tion” that would ex­empt Ste­lara from Medicare price ne­go­ti­a­tions un­der the In­fla­tion Re­duc­tion Act.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER